Radiation and hormone therapy after surgery cures breast cancer

October 17, 2005

The current standard of care for early-stage breast cancer is breast conserving surgery (lumpectomy) to remove the tumor followed by radiation and hormone therapy to kill any remaining cells. Physicians in Austria tested whether patients were more likely to have their cancer return if radiation therapy was removed from the mix. They found that radiation therapy combined with hormone therapy after surgery is more effective in keeping the cancer from returning, according to a study presented October 17, 2005, at the American Society for Therapeutic Radiology and Oncology's 47th Annual Meeting in Denver.

The study, conducted between 1996 and 2004, enrolled 869 women into the Austrian Breast and Colorectal Cancer Study Group. The patients were randomly split into two groups: one receiving whole breast radiation therapy (with a boost to the tumor bed) plus hormone therapy (either Tamoxifin or Arimidex) after surgery and one receiving only hormone therapy following surgery.

The results show a significant reduction in cancer returning in the breast among the patients who received radiation. Only one relapse in the radiation/hormone therapy group was observed compared with 13 relapses in the hormone therapy only group. Although the radiation therapy helped prevent the breast cancer from returning, researchers found patients in both groups lived just as long and were just as likely to have the cancer spread to other parts of the body.

"The overall survival rate was excellent at 97 percent. Although the overall survival rate for both patients was unchanged, radiation therapy as part of the post-lumpectomy regimen prevents the recurrence of cancer in the breast by almost 100 percent," said Richard Poetter, M.D., lead author of the study and a radiation oncologist at the University Clinic for Radiotherapy and Radiobiology in Vienna, Austria. "It seems that the current standard of care of surgery followed by radiation and hormone therapy is the best treatment for women with early-stage breast cancer."

For more information on radiation therapy for breast cancer, please visit www.rtanswers.org or call 1-800-986-7876 for a free brochure.

If you would like a copy of the abstract, "Lumpectomy Plus Tamoxifen or Arimidex With or Without Whole Breast Irradiation in Women With Favorable Early Breast Cancer," or you would like to speak to the lead author of the study, Richard Poetter, M.D., please call Beth Bukata or Nick Lashinsky October 16-20 in the ASTRO Press Room at the Colorado Convention Center at 303-228-8454 or 303-228-8455. You may also e-mail them at bethb@astro.org or nickl@astro.org.
-end-
ASTRO is the largest radiation oncology society in the world, with more than 8,000 members who specialize in treating patients with radiation therapies. As a leading organization in radiation oncology, biology and physics, the Society is dedicated to the advancement of the practice of radiation oncology by promoting excellence in patient care, providing opportunities for educational and professional development, promoting research and disseminating research results and representing radiation oncology in a rapidly evolving socioeconomic healthcare environment.

American Society for Radiation Oncology

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.